Aroa Biosurgery Ltd Market Cap ($118.99 Million)
Market Cap & Net Worth: Aroa Biosurgery Ltd (ARX)
Aroa Biosurgery Ltd market cap. Aroa Biosurgery Ltd (AU:ARX) has a market capitalization of $118.99 Million (AU$168.18 Million) as of November 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #18347 globally and #555 in its home market, demonstrating a -6.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aroa Biosurgery Ltd's stock price AU$0.49 by its total outstanding shares 346753508 (346.75 Million). Also see ARX cash flow conversion for how efficiently the company converts equity into cash flow.
Aroa Biosurgery Ltd Market Cap History (2020–2026)
Aroa Biosurgery Ltd market cap history from 2020 to 2026. Data shows change from $282.15 Million to $118.99 Million (-15.03% CAGR). Check today's stock price for Aroa Biosurgery Ltd for real-time trading data and today's change.
Aroa Biosurgery Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aroa Biosurgery Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Aroa Biosurgery Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
2.36x
Aroa Biosurgery Ltd's market cap is 2.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $282.15 Million | $23.83 Million | -$5.66 Million | 11.84x | N/A |
| 2021 | $250.26 Million | $20.51 Million | -$17.63 Million | 12.20x | N/A |
| 2022 | $264.98 Million | $36.88 Million | -$7.79 Million | 7.18x | N/A |
| 2023 | $203.64 Million | $59.31 Million | -$370.68K | 3.43x | N/A |
| 2024 | $188.92 Million | $63.36 Million | -$9.75 Million | 2.98x | N/A |
| 2025 | $181.56 Million | $76.97 Million | -$3.47 Million | 2.36x | N/A |
Competitor Companies of ARX by Market Capitalization
Companies near Aroa Biosurgery Ltd in the global market cap rankings as of November 6, 2026. Also see Aroa Biosurgery Ltd (ARX) total assets for a full breakdown of the balance sheet.
Key companies related to Aroa Biosurgery Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #107 globally with a market cap of $196.11 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #182 globally with a market cap of $130.04 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #225 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #237 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #107 | Abbott Laboratories | NYSE:ABT | $196.11 Billion | $115.51 |
| #182 | Stryker Corporation | NYSE:SYK | $130.04 Billion | $339.65 |
| #225 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $104.96 |
| #237 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Aroa Biosurgery Ltd (2020–2026)
Market capitalization of Aroa Biosurgery Ltd from 2020 to today. Between 2020 and today, Aroa Biosurgery Ltd's market cap moved from $282.15 Million to $ 118.99 Million, with a yearly change of -15.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$118.99 Million | -34.46% |
| 2025 | AU$181.56 Million | -3.90% |
| 2024 | AU$188.92 Million | -7.23% |
| 2023 | AU$203.64 Million | -23.15% |
| 2022 | AU$264.98 Million | +5.88% |
| 2021 | AU$250.26 Million | -11.30% |
| 2020 | AU$282.15 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Aroa Biosurgery Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $118.99 Million USD |
| MoneyControl | $118.99 Million USD |
| MarketWatch | $118.99 Million USD |
| marketcap.company | $118.99 Million USD |
| Reuters | $118.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aroa Biosurgery Ltd
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more